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lolecular imaging is a unique research
discipline with the potential to detect
disease in pre-clinical and early stages.
It integrates fields of clinical medi-
ine, cell biology, and signal transduction for ap-
ropriate selection of target to be imaged, and
ynthetic chemistry and imaging sciences for
haracterization of the pathology. In contrast to
raditional diagnostic techniques, molecular imag-
ng employs noninvasive, quantitative, and repeti-
ively feasible strategy of imaging targeted biolog-
cal processes at both cellular and subcellular
evels within a living organism (1).
Due to recent advances in nanotechnology and
ngineering innovations, molecular imaging has
ndergone profound change during its rather
hort development period as a scientific discipline.
y weaving medicine and computer technology
ogether, molecular imaging has uncovered sim-
licity behind the complexity of diseases. It has
ffered quantitative assessment of pathophysiol-
gy, altered metabolic states, subcellular processes,
eceptor modifications, and message or gene ex-
ression in various disorders. To effectively de-
elop the concept of molecular imaging, it has be-
ome essential that we demonstrate the feasibility
f imaging in small transgenic animal models.
his has stimulated the development of advanced
mall animal imaging technology including mi-
roscale positron emission tomography, single-
hoton emission computed tomography, com-a
From the University of California Irvine, Irvine, California; and the
University of Maryland School of Medicine, Baltimore, Maryland.uted tomography, magnetic resonance imaging,
igh-frequency ultrasound, and optical fluoro-
hrome or bioluminescence imaging. It is ex-
ected that fusion technology involving computed
omography, magnetic resonance imaging, or ul-
rasound imaging combined with nuclear or opti-
al imaging would not only provide both morpho-
ogical and functional information, but also better
ocalization of hitherto difficult foci of tracer
ptake.
It is exciting that the National Cancer Institute
as identified molecular imaging as 1 of the 6
ost rewarding opportunities for development
2), and a major thrust has been placed on molec-
lar imaging in the newly formed National Insti-
ute of Biomedical Imaging and Biomedical Engi-
eering. Although the National Heart, Lung, and
lood Institute has yet to fully embrace this ini-
iative, the field of cardiovascular molecular imag-
ng has slowly but surely progressed. In addition
o addressing a diagnostic query, we strongly be-
ieve that targeting of key steps in cellular or sub-
ellular biologic processes further clarifies critical
athogenetic pathways. The pathophysiology of a
isease process and development of targeted im-
ging are interdependent and complementary. Re-
iew of the historical evolution of any molecular
maging strategy should substantiate our claim.
et’s consider the imaging of apoptosis in myo-
ardium. It becomes amply clear that targeting
f a cell membrane phospholipid, phosphatidyl
erine (PS, a hallmark of apoptosis), not only al-
owed development of a diagnostic tool, but has
lso led to better understanding of reversibility of
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407poptotic process, in turn expanding diagnostic
pplications and proposing novel intervention
trategies.
Apoptosis, a programmed cell death process,
onstitutes an integral part of the pathology asso-
iated with ischemic or inflammatory state of the
yocardium (3); it is believed to precede the ne-
rotic change. It has been proposed that noninva-
ive imaging of apoptosis may allow early identifi-
ation of myocardial damage and since damage
ollows an ordained cascade, it may be amenable
o recovery. The apoptosis-inducing stimuli usu-
lly converge to release various mitochondrial pro-
eins into a cytoplasmic compartment, which ini-
iate a chain reaction to activate highly specific
roteolytic enzymes, referred to as terminal
aspases, such as caspase-3 (4). Activation of
aspase-3 is linked to the loss of asymmetry of
hospholipid distribution between the inner and
uter cell membrane layers, and has been ex-
loited as one method of apoptosis imaging. PS,
hich is normally restricted to the inner mem-
rane tablet is exteriorized to the outer cell mem-
rane layer, and has been targeted by appropri-
tely labeled annexin A5 (AA5) for in vitro and
n vivo imaging; AA5 is a normally circulating
rotein and has a nanomolar affinity for PS. Ele-
ant cell culture experiments had paved the way
or initial imaging of apoptotic cells, and a radio-
abeled AA5 has been used clinically for molecu-
ar imaging of apoptosis in myocardial infarction
nd transplant rejection (5–7). As expected, the
A5 uptake was confined to the coronary distri-
ution territory in the infracted myocardium,
hich corresponded to the perfusion deficit. On
he other hand, a diffuse or multifocal uptake was
bserved in the inflammatory state not limited to
coronary distribution. As postulated by the basic
cience tenets, use of broad caspase inhibitor,
VAD-fmk, not only restricted the extent of
yocardial injury verified by annexin uptake, it
lso delayed the onset and slowed the rate of oc-
urrence of myocardial damage in experimentally-
nduced murine myocardial infarction (8–11).
hese preclinical studies have demonstrated a di-
ect correlation between the extent of apoptosis
efined by AA5 uptake and the tell-tale histologic
haracteristics, thus establishing grounds for po-
ential clinical trials (11). BWhen these studies were underway, it was be-
oming clear that apoptosis precedes onset of ne-
rosis and, therefore, pre-necrotic ischemic state
hould already be associated with PS externaliza-
ion. As such, AA5 imaging was attempted in the
rief ischemic episodes with the premise that
A5 imaging would permit positive imaging of
nducible ischemia in a myocardial perfusion neg-
tive zone (12). Experimental evidence confirmed
A5 uptake and biochemical activation of
aspase-3, but was not verified by histologic evi-
ence of either apoptosis or necrosis. Ultracen-
rifugal separation of myocardial homogenates
urprisingly recovered radiolabeled AA5 from the
ytoplasmic compartment suggesting the internal-
zation of PS-bound AA5. Subsequently, a series
f experiments revealed that PS exteriorization
ccur within 5 min of ischemic insult, which is
reventable by preadministration of caspase inhib-
tors (13). In the absence of caspase inhibitors, PS
emains expressed on the outer cell membrane up
o at least 6 h after resolution of brief ischemia,
otentially facilitating after-the-fact imaging of
schemia. The PS externalization was found to be
continuous process until caspase-3 activation
pontaneously resolved. The PS-bound AA5 tri-
erized between 10 to 20 min and invaginated a
embrane patch into the cytoplasm as a vesicle
nd removed the PS from surface; persistent ex-
ression of PS would have constituted an “eat-
e-signal” for phagocytosis of the doomed cell. It
ecomes much clearer from the aforementioned
escription that whereas bench-side cues are im-
ortant for development of molecular imaging,
he observations made by molecular imaging
qually and substantially contribute to a better
nderstanding of the disease process.
The story goes a bit further into apoptosis im-
ging of the myocardium. A slow and smoldering
poptosis occurs in remodeling myocardium and
ontributes to an inexorable decline in ventricular
unction in heart failure (HF). Cytokine and/or
xidative stress results in release of cytochrome c
rom the mitchondria into cytoplasmic compart-
ent, and consequent activation of pro-apoptotic
aspase-3 results in myofilament proteolysis and
NA fragmentation (14). However, simultaneous
pregulation of antiapoptotic factors, such as
Cl2- and XIAP-like proteins, and loss of DNA
f
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408ragmentation factors prevent completion of apop-
otic process (apoptos is interruptus) (4,15). The
mount of activated caspase-3 is determined by
he balance of antiapoptotic and proapoptotic fac-
ors. Because caspase-3 is activated in HF, it was
roposed that the attendant PS externalization
hould be amenable to AA5 imaging in HF (1).
he AA5 uptake was observed in up to 45% of
atients with worsening HF, who went on to
emonstrate a 10% decrease in their ejection frac-
ion after 1-year follow up. On the other hand,
he remaining patients with negative scans im-
roved LV function by 7% in the follow-up. The
esults suggested that fewer the endogenous anti-
poptotic factors, the greater the residual
aspase-3, the more PS externalization, the higher
ikelihood of an AA5-positive scan, the poorer
he prognosis, and the greater the necessity for
upportive therapy. It is evident from the forego-
ng discussion that AA5 imaging has contributed
mmensely to our understanding of the intricacies
f heart muscle cell damage in various cardiovascu-
ar diseases (Table 1).
The convergence of disciplines in medicine,
olecular and cellular biology, and computer
echnology will likely translate into development
f better diagnostic and management strategies. It
s important that we strive to understand the
athogenesis of various cardiovascular disorders.
dentification of the worthy targets which are
rominently overexpressed in the diseased tissue
ould provide a high target-to-background con-
rast for hot-spot imaging. Alternatively, identifi-
Molecular Imaging of Apoptosis in Myocardium
enetic Basis of Imaging Imaging Results
is and necrosis in the
of myocardial damage
AA5 uptake observed in the areas
corresponding to perfusion deﬁcit (5)
is precedes necrosis (1) AA5 uptake observed in ischemic area n
associated with histoloically-veriﬁed
apoptosis or necrosis; AA5 recovered
from cytoplasm (11)
te apoptosis contributes
tricular dysfunction
)
In worsening HF patients AA5 uptake is
associated with poor outcome (16)ation of moieties which are conspicuously absent Erom the target tissue would allow a cold-spot
attern of imaging. Molecular imaging is not lim-
ted by imaging modality. Once a target and tar-
eting agent is identified, the imaging can be per-
ormed by conjugation of the imaging probe with
ppropriate reporting tracer and the target should
ecome amenable to respective modality of imag-
ng. In this issue of the JACC: Cardiovascular Im-
ging, one of the papers proposes the imaging of
ngiotensin-II type 1 receptors, which is likely to
ncover susceptibility to the development of ad-
erse myocardial remodeling and HF (17). The
aper (17) and the editorial comment (18) are
inked to CVN interviews that highlight the
ole that molecular imaging will play in clinical
edicine. It is mandatory that an effort be
ade to express the conceptual premises and
ractical execution in a simplified manner so as
o stimulate close collaboration among the cli-
icians, biologists, and imagers alike. Molecular
maging teaches us that targets are a plenty in
ealth and disease, each with a story to tell.
maging and imagers are the future story tell-
rs, the Rosetta stone of pathophysiology and
dvanced therapeutics.
Happy targeting, folks!
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Imaging Leading to Pathogenetic Clues
Caspase inhibitors resolve AA5 uptake (8,10), decrease both
apoptosis and necrosis (9), establish apoptosis-necrosis
continuum, extend window for intervention (8)
Transient PS expression and AA5 uptake, AA5 removes PS from
membrane by invagination as a protective phenomenon (13),
caspase inhibition hastens recovery
Simultaneous upregulation of pro- and anti-apoptotic factors
establish the basis of incomplete apoptosis in heart failure
and suggest novel avenue for reverse remodeling (4,16)Table 1. Evolution of
Disease
Process Pathog
Myocardial
infarction
Apoptos
areas
(1)
Myocardial
ischemia
Apoptos ot
Heart
failure
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